Cytocore Inc

(OTC: CYOE)

Industry: Medical Equipment
On the web: http://www.CytoCoreInc.com
Employees: 9

CytoCore, Inc., formerly Molecular Diagnostics, Inc. was incorporated in Delaware in December 1998 as the successor to Bell National Corporation, a Company incorporated in California in 1958. Bell National merged into Ampersand Medical Corporation, its wholly-owned subsidiary, in May 1999 in order to change the state of incorporation of the Company to Delaware. In 2006, the Company's corporate name was changed from Molecular Diagnostics, Inc. to CytoCore, Inc., which change was effected in Delaware in June 2006. CCI develops, manufactures and sells an integrated family of cost-effective products for the detection, diagnosis and treatment of cancer under the trade name of CytoCore Solutions(tm). CytoCore Solutions products are intended to address sample collection, specimen preparation, specimen evaluation, and patient treatment and monitoring within vertical markets related to specific cancers. Current CytoCore Solutions products are focused upon cervical cancer. CCI plans that this focus would later be expanded to include other gynecological cancers as well as bladder, lung, and breast cancers, among others. Within each of these markets, CCI anticipates that the CytoCore Solutions products would be sold as individual value-added drop-in replacements for existing products and as integrated systems that improve the efficiency and effectiveness of clinical and laboratory operations. In addition, most CytoCore Solutions products are designed to support multiple markets, thus providing the customer with a comprehensive and internally consistent migration path as new disease-specific products are added to the CytoCore portfolio. CCI's main product is the SoftPAP(r), a cell collection device intended to replace the spatula and brush currently used to collect patient cytology samples. It constitutes the cell collection component of the Company's CytoCore Solutions System. The Company is also licensed to sell the PadKit(r), another sample collection device directed at ensuring female reproductive tract health. CCI intends to market and sell the SoftPAP and PadKit devices along with GluCyte(tm), a cell preservative developed by Cell Solutions LLC. The other components of the CytoCore Solutions System include certain biochemical assays and slide-based tests, the Company's next generation system for computer-assisted cytology - the Automated Image Proteomic System or AIPS(tm)- and a drug delivery system. The Company owns the trademarks - SoftPAP, CytoCore(tm, CytoCore Solutions and Cocktail-CVX(tm). The Company manages the regulatory process through the use of consultants and clinical research organizations. CCI's prospective foreign operations are also subject to government regulation, which varies from country to country.